GeneralConnection.com ➔ Dictionary
Dictionary Search

achondroplasia

Synonyms

Noun

1. achondroplasty

2. osteosclerosis congenita, chondrodystrophy, genetic disease, genetic disorder, genetic abnormality, genetic defect, congenital disease, inherited disease, inherited disorder, hereditary disease, hereditary condition

Usage
Jake Birecki: Making Space of Strength, Sports and Self - BioMarin Pharmaceutical
Abbisko Therapeutics' FGFR2/3 inhibitor ABSK061 receives FDA IND clearance for achondroplasia in children - Select Science
Excess FGFR3 signaling in achondroplasia disrupts turnover of resting zone chondrocytes via CREB signaling - Nature
BioMarin, Ascendis slide as BridgeBio shakes up achondroplasia landscape - MSN
Homozygous Achondroplasia With Long-Term Survival: Growth Patterns, Medical Interventions, and Practice Implications - Wiley Online Library
Finding the right team for achondroplasia: Jeremy’s story - Boston Children's Answers
Once-Weekly Navepegritide Safe and Efficacious for Achondroplasia, With Carlos Bacino, MD - HCPLive
BioMarin’s BMN 333 Takes On Vosoritide in High Stakes Achondroplasia Trial - TipRanks
Oral infigratinib boosts growth velocity in achondroplasia study - 2 Minute Medicine
COACH trial: hGH accelerates CNP benefits in achondroplasia - The Clinical Trial Vanguard
Achondroplasia - The Lancet
Oral medication boosts annualized height velocity for children with achondroplasia - Healio
UK consensus guidelines for multidisciplinary care of children and young people with achondroplasia: a modified Delphi process - Archives of Disease in Childhood
New treatment gives hope to children with achondroplasia - Loma Linda University
‘Highly Impressive’ Data Propels BridgeBio’s Achondroplasia Drug Forward - BioSpace
Ascendis gains more altitude with FDA approval for dwarfism drug Yuviwel - Fierce Pharma
FDA approves dwarfism drug - Nature
Ascendis Enters Achondroplasia Arena as FDA Approves First Weekly Drug - BioSpace
Combination Navepegritide, Lonapegsomatropin Shows Durable Benefit in Phase 2 Pediatric Achondroplasia Trial - HCPLive
Once-weekly navepegritide plus lonapegsomatropin demonstrates growth in children with achondroplasia - Contemporary Pediatrics
Oral infigratinib linked to improved growth and proportionality in achondroplasia - Contemporary Pediatrics
Oral Infigratinib Meets Annualized Height Velocity Endpoint in Phase 3 Achondroplasia Trial - HCPLive
How Turner and Achondroplasia Data plus Board Addition Could Shape Ascendis Pharma’s (ASND) Pipeline Strategy - Yahoo Finance
FDA pushes back decision on Ascendis' achondroplasia drug to February - FirstWord Pharma
New mouse model uncovers achondroplasia's cellular growth plate dysregulation - News-Medical
The latest on navepegritide for children with achondroplasia, with Carlos Bacino, MD - Contemporary Pediatrics
Ascendis Readies BioMarin Challenge in Achondroplasia While Others Search for Root Cause - BioSpace
BridgeBio drug for genetic cause of dwarfism succeeds in key study - statnews.com
Once-weekly agent boosts annualized growth velocity for children with achondroplasia - Healio
First-of-its-kind trial boosts growth in children with rare disorders - Children's National Hospital
Ascendis reports arm span, spinal improvements in achondroplasia trial - Investing.com
FDA Grants Accelerated Approval to Navepegritide for Achondroplasia in Children Aged 2 Years and Older - HCPLive
Abbisko Therapeutics' FGFR2/3 Inhibitor ABSK061 Receives FDA IND Clearance for Achondroplasia in Children - Yahoo Finance
COACH Trial Confirms Durable Benefits in Achondroplasia - The Clinical Trial Vanguard
Once-Weekly Treatment Approved for Achondroplasia in Kids - MedPage Today
BridgeBio preps approval push after dwarfism drug increases children's height in phase 3 - Fierce Biotech
BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis - BioPharma Dive
Navepegritide demonstrates growth velocity, skeletal alignment in children with achondroplasia - Contemporary Pediatrics
Tyra Biosciences initiates paediatric study for achondroplasia treatment - Clinical Trials Arena
Tyra Biosciences Announces First Child Dosed in BEACH301, its Phase 2 Study for Dabogratinib (TYRA-300) in Pediatric Achondroplasia - PR Newswire
Ascendis Pharma Receives FDA Approval for YUVIWEL®, First Once-Weekly Treatment for Achondroplasia in Children - Quiver Quantitative
United States Achondroplasia Market 2026 | Growth Drivers, Key Players & Investment Opportunities - openPR.com
Ascendis Pharma Launches Achondroplasia Treatment Following FDA Approval - HarianBasis.co
Why BridgeBio Pharma (BBIO) Is Up 10.6% After Breakthrough Phase 3 Infigratinib Data In Achondroplasia - Yahoo Finance
BridgeBio looks to challenge BioMarin in dwarfism market on Phase III win - Clinical Trials Arena
Drug Combo ‘Potentially Revolutionary’ for Achondroplasia - Medscape
FDA Delays Decision on Ascendis’ Dwarfism Drug by Three Months - BioSpace
Novel Combination Improved Growth in Kids With Achondroplasia, Study Suggests - MedPage Today
Assessing Abbisko Cayman (SEHK:2256) Valuation After FDA Clears ABSK061 IND For Pediatric Achondroplasia - Yahoo Finance
How Investors May Respond To Ascendis Pharma (ASND) Achondroplasia Combo Data And YUVIWEL Launch - Sahm
New Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP’s Benefits Beyond Linear Growth in Children with Achondroplasia - Yahoo Finance
Camp Ellellbee Creates Space for Connection, Joy and Open Conversations About Skeletal Conditions - BioMarin Pharmaceutical
FDA approves Ascendis’ once-weekly achondroplasia treatment - Investing.com
Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH) - Yahoo Finance
BridgeBio's oral drug boosts growth in children with dwarfism in late-stage trial - Reuters
FDA Okays Weekly Option in Achondroplasia - Conexiant
Inside pharma’s race to deliver new treatments for dwarfism - Pharma Voice
BridgeBio stock jumps after positive Phase 3 results for achondroplasia drug - Investing.com
New Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026 - Yahoo Finance
Early VOXZOGO Data May Reshape BioMarin Growth Expectations In Achondroplasia - simplywall.st
FDA delays decision on Ascendis' dwarfism prospect by 3 months - Fierce Biotech
Here we grow: chondrocytes’ behavior reveals novel targets for bone growth disorders - Asia Research News |
Ascendis Submits Marketing Authorisation Application to the - GlobeNewswire
Ascendis reports strong results for achondroplasia combination therapy - Investing.com
BridgeBio Confident Infigratinib Can Steal Achondroplasia Market Share - Citeline News & Insights
Ascendis wins FDA approval for achondroplasia drug, waits on EU action - Endpoints News
US FDA clears four NMEs, including those for dermatitis, achondroplasia - BioWorld News
BioMarin Pauses Dosing, Enrollment in 2 Voxzogo Studies After Safety Signal - BioSpace
BioMarin reports growth data for achondroplasia drug VOXZOGO - Investing.com
Ascendis Announces Extension of FDA Review Period for - GlobeNewswire
Ascendis Pharma Secures U.S. Orphan Drug Exclusivity and Launches YUVIWEL for Achondroplasia - TipRanks
BioMarin pumps brakes on 3 Voxzogo studies as competition in drug's flagship achondroplasia indication mounts - Fierce Pharma
BioMarin, Ascendis stocks fall after BridgeBio’s positive achondroplasia data - Investing.com
BioMarin Bet on Amicus To Ease Voxzogo’s Decline. Will It Work? - BioSpace
Ascendis reports interim analysis outcomes from achondroplasia trial - Clinical Trials Arena
BridgeBio Pharma (BBIO) Valuation Check After Strong Phase 3 PROPEL 3 Results In Achondroplasia - Yahoo Finance
Abbisko Wins FDA IND Clearance for Pediatric Achondroplasia Drug ABSK061 - TipRanks
Weekly achondroplasia drug combo posts 9.4 cm arm span gain in 52 weeks - Stock Titan
Ribomic’s RBM-007 ready for phase III in achondroplasia - BioWorld News
FDA accepts navepegritide application to treat children with achondroplasia - Contemporary Pediatrics
FDA Approves Once-Weekly Yuviwel® (Navepegritide) For Children With Achondroplasia Aged 2 Years And Older - TradingView
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia - Bitget
Can TransCon CNP Reshape Achondroplasia Treatment? FDA Decision Due Nov. 30 - RTTNews
Dwarfism golden gate? Bridgebio’s infigratinib phase III hits - BioWorld News
New Two-Year Data from Pivotal ApproaCH Trial Showing - GlobeNewswire
Tyra Biosciences Narrows Dabogratinib Focus, Teases Mid-Year NMIBC and 2H Achondroplasia Data - Yahoo Finance
BridgeBio Pharma Touts Strong Phase 3 PROPEL-3 Data for Oral Infigratinib in Achondroplasia - Yahoo Finance
BridgeBio Pharma Investor Update: PROPEL 3 “Last Visit” Set as Infigratinib Phase 3 Readout Nears - Yahoo Finance
BridgeBio gains on phase 3 dwarfism data - pharmaphorum
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia - Yahoo Finance
GLP-1s Bringing Back Scurvy? Achondroplasia Drug Win; Intermittent Fasting Flop - MedPage Today
Biomarin Receives Health Canada Notice Of Compliance With Conditions For Voxzogo®, For Achondroplasia - TradingView
BridgeBio Announces Positive Phase 3 Achondroplasia Trial Results - TipRanks
BioMarin touts promising early result for potential Voxzogo successor - Fierce Pharma
Positive data: Navepegritide, lonapegsomatropin combination treatment for children with achondroplasia - Contemporary Pediatrics
Ascendis scores FDA approval for weekly dwarfism drug - pharmaphorum
Doctor helps Colorado boy with dwarfism thrive at school - KUSA.com
BridgeBio data for dwarfism drug sets up showdown with BioMarin's Voxzogo - FirstWord Pharma
BridgeBio Pharma shares rise on ‘compelling’ Phase 3 trial results for achondroplasia drug - Proactive financial news
INTERNATIONAL DWARFISM AWARENESS DAY - National Day Calendar
Foreign Language Equivalents
Foreign Language Equivalents of 'achondroplasia'
Language Equivalent   Language Equivalent
French achondroplasie    Spanish
Misspellings - Typos
acondroplasia,   achondropllasia,   achondroplasis,   achnodroplasia,   achondrpolasia,   achondrroplasia,   achondroplasoa,   chondroplasia,   cahondroplasia,   achondroplasa,   achondroplssia,   achondroplsaia,   achodroplasia,   achodnroplasia,   achhondroplasia,   achoondroplasia,   achonsroplasia,   axhondroplasia,   avhondroplasia,   achondrop;asia,   achondtoplasia,   achondropalsia,   achondrolpasia,   achondroplsia,   achondroolasia,   achondriplasia,   ahcondroplasia,   achondroplassia,   achondroplaaia,   achonfroplasia,   achondropasia,   acjondroplasia,   aachondroplasia,   acohndroplasia,   achondroplaisa,   achondro[lasia,   achindroplasia,   achondrolasia,   achonroplasia,   schondroplasia,   achonrdoplasia,   achondroplaasia,   achondroplasua,   acchondroplasia,   achondroplasiia,   achondroplasai,   acgondroplasia,   achondropladia,   achpndroplasia,   achobdroplasia,   achondeoplasia,   achonndroplasia,   achonddroplasia,   achondrpplasia,   ahondroplasia,   achondropkasia,   achomdroplasia,   achondroplasi,   achondroplasiaa,   achondropplasia,   achondroplaia,   achondrplasia,   achndroplasia,   achondorplasia,   achondrooplasia,   achondoplasia
Words Starting with Letter - 'B'
bannister bannock bannockburn
banns banquet banquet song
banqueting banquette banshee
bantam bantamweight banteng
banter bantering banteringly
banti's disease banti's syndrome banting
bantoid bantoid language bantu
bantu-speaking banyan banyan tree
« Go to Page 38            Go to Page 40 »   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z